Fdanewsdrugdailybulletin

Dec. 17, 2018

Vol. 15 No. 243

View Archived Issues

Sign Up Now

FDA Approves Tecentriq Plus Avastin and Chemotherapy for NSCLC

The agency based its approval on a Phase 3 trial that showed the regimen led to patients living significantly longer than with Avastin and chemotherapy alone. Read More

CMS Report: Retail Drug Spending Slowed in 2017

CMS said the catalysts for slower retail drug spending include slower growth in the number of prescriptions dispensed and slower volume growth of expensive drugs. Read More

FDA Hits Immunomedics for Data Integrity Breach

The firm gave no assurance that samples and batch records from commercial batches it manufactured before the data integrity breach were not impacted. Read More

IFPMA Updates Ethics Code to Ban Gifts from Drugmakers

The code bans nonmonetary gifts for the promotion of prescription-only drugs, but it allows for promotional aids “of minimal value and quantity” for over-the-counter drugs. Read More

NIH Pressured to Keep CAR-T Therapy Affordable Before Granting License

The groups urged the NIH to include provisions in the license to restrain prices. Read More